Open Access Open Badges Research article

Prevalence of metabolic syndrome among patients with Schizophrenia in Palestine

Waleed M Sweileh*, Sa’ed H Zyoud, Salah A Dalal, Sami Ibwini, Ansam F Sawalha and Iyad Ali

Author Affiliations

College of Medicine and Health Sciences, Division of Pharmacy An-Najah National University, Nablus, Palestine

For all author emails, please log on.

BMC Psychiatry 2012, 12:235  doi:10.1186/1471-244X-12-235

Published: 27 December 2012



Metabolic syndrome (MS) is a cluster of the most dangerous cardiac risk factors and is associated with high mortality. Ethnic differences in metabolic syndrome (MS) criteria and prevalence rates have been reported. The purpose of this study was to investigate the MS prevalence among patients with schizophrenia in Palestine.


We recruited 250 patients with schizophrenia from 4 psychiatric primary healthcare centers in Northern Palestine. The MS prevalence was assessed based on National Cholesterol Education Program Adult Treatment Panel III Adapted criteria.


The overall MS prevalence was 43.6%, with 39% in male and 55.9% in female patients. On average, the study patients had 2.3 ± 1.3 metabolic abnormalities. Univariate analysis showed that MS was significantly higher with older age, female gender, longer duration of the illness, smoking, abdominal obesity, high systolic and diastolic blood pressure, high triglycerides, low HDL-C, and high fasting plasma glucose. Multiple logistic regression analysis showed that only systolic blood pressure, high triglycerides, high fasting plasma glucose, and low HDL-C were significant predictors of MS in schizophrenic patients.


MS is common among Arab patients with schizophrenia. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors.

Schizophrenia; Metabolic syndrome; Palestine